OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Comparative Effectiveness Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Cost–effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more	146
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis	42
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis	41
Engaging veterans in the research process: a practical guide	36
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary	28
An observational cohort study of pelvic floor photobiomodulation for treatment of chronic pelvic pain	28
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis	25
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis	22
Journal of Comparative Effectiveness Research : 2022 year in review	22
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database	22
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy	21
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea	20
Discharges against medical advice and 30-day healthcare costs: an analysis of commercially insured adults	20
Corrigendum	20
Impact of clinical research coordinators on research output in orthopedic surgery	19
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study	19
Cost–effectiveness analysis of a resource-intensive approach versus minimally invasive strategy for high-risk transcatheter aortic valve replacement patients	19
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 20	19
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies	16
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis	16
Letter in reply	15
Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims	15
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity	14
Clinical assessment of the potential use of a novel single-dose prefilled injection device for the administration of Acthar Gel in children: a narrative review	14
Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies	14

The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA	13
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience	13
Healthcare utilization and costs following molecular diagnostic testing among patients with vaginitis	13
R WE ready for reimbursement? A round up of developments in real-world evidence relating to HTA: part 3	12
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?	12
Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China	12
Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases	12
Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis	12
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer	12
Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab	11
Cost–effectiveness of lung cancer screening with volume computed tomography in Portugal	11
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients	11
A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis	11
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada	10
Corrigendum	10
Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations	10
Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients	10
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	10
To replicate or not to replicate? Insights and interpretations from a randomized trial duplication initiative	9
Evidence-based public policy making for medicines across countries: findings and implications for the future	9
Comparison of intravenous versus topical tranexamic acid in primary total hip arthroplasty: a systematic review and meta-analysis of ten randomized trials	9
Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies	9
Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors	9
How the use of standardized protocols may paradoxically worsen disparities for safety-net hospitals	9
The triple win – implementation science benefits patients, healthcare systems and industry alike	9
Evaluation of patient/caregiver and healthcare provider knowledge, attitudes and behavior for safety and use of pexidartinib	9
Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes	9
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer	9
Cost–utility analysis of single nucleotide polymorphism panel-based machine learning algorithm to predict risk of opioid use disorder	9
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer	9
Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol	8
Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma	8
Impact of COVID-19 on chronic pain structures: data from French national survey	8
Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practic	8
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	8
Impact analysis of expanding narrow-spectrum antibiotic use for children with ear, sinus and throat infections	8
Comparison of Enterprise stent 2 with 1 in assisting coiling of ruptured aneurysms: a real-world study	8
Diversity in clinical trial inclusion for peripheral artery disease lower extremity endovascular interventions: a systematic review protocol	8
Characterization of medical device randomized controlled trials with adaptive designs	8
Healthcare resource utilization and costs in pediatric pulmonary arterial hypertension in a third-level hospital in Mexico	8
Comparative effectiveness research in COVID-19 using real-world data: methodological considerations	7
Access in all areas? A round up of developments in market access and health technology assessment: part 1	7
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis	7
Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome	7
Tr14 gel for the treatment of acute ankle sprains: a plain language summary of the TRAUMED trial	7
Cost–effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes	7
Single-arm oncology trials and the nature of external controls arms	7
The effects of Pilates on pain, functionality, quality of life, flexibility and endurance in lumbar disc herniation	7
COVID-19 clinical trials: who is likely to participate and why?	7
Uricemia in the acute phase of myocardial infarction and its relation to long-term mortality risk	7

Does off-hours endoscopic hemostasis affect outcomes of nonvariceal upper gastrointestinal bleeding?	7
Rivaroxaban versus low-molecular-weight heparins for short- and long-term prognosis in patients with deep vein thrombosis after spontaneous intracranial hemorrhage	7
Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care	7
An impact evaluation of an education bundle for patients at risk of developing venous thromboembolism	7
Expanding the learning health system model to be health literate	6
Assessing the change in disease severity based on depressive symptoms in real-world psoriasis patients	6
A value-based budget impact model for dronedarone compared with other rhythm control strategies	6
Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling	6
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10	6
Navigating adalimumab biosimilars: an expert opinion	6
Corrigendum	6
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD	6
The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives	6
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design	6
Use of transportability methods for real-world evidence generation: a review of current applications	6
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications	6
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers	6
Quality in qualitative evidence: new best practice principles from NICE’s real-world evidence framework	6
An economic evaluation of teledermatology care delivery for chronic skin diseases	6
Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China	6
Treatment goals for rheumatoid arthritis: patient engagement and goal collection	6
Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary	6
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma	6
Burden of illness for patients with primary biliary cholangitis: an observational study of clinical characteristics and healthcare resource utilization	6
COVID-19 complications in males and females: recent developments	5
Economic impact of reduced postoperative visits after inflatable penile prosthesis implantation	5
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant	5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15	5
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib	5
Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here	5
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges	5
QDOT MICRO™ versus THERMOCOOL ^® SMARTTOUCH™ and THERMOCOOL SMARTTOUCH ^® Surround Flow in radiofrequency ablation of paroxysmal atr	5
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US	5
Robotic-assisted total hip arthroplasty: an economic analysis	5
In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database	5
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions	5
Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data	5
Expert perspectives on the use of safinamide for Parkinson’s disease in Portugal: insights from a Portuguese Delphi Consensus	5
Economic burden of lives lost due to COVID-19 in California State	4
Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes	4
Visualizing the target estimand in comparative effectiveness studies with multiple treatments	4
Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs	4
An international observational study assessing conservative management in hemorrhoidal disease: results of CHORALIS (aCute HemORrhoidal disease evALuation International Study)	4
Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis	4
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data inROS1+ NSCLC	4
Respiratory and nonrespiratory COVID-19 complications in patients with obesity: recent developments	4
R WE ready for reimbursement? A round up of developments in RWE relating to health technology assessment: part 2	4
Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma	4
Budget impact analyses of hemoglobin A1c and lipid panel point-of-care testing with Afinion™ 2 in Canada and Italy	4
Potential policy reforms to strengthen the accelerated approval pathway	4
Val (EU) xit: do we need an international ISPOR value flower?	4
Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data	4
The need to consider market access for pharmaceutical investment decisions: a primer	4
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 4	4
Impact analysis of expanded access to ketamine for treatment-resistant depression	4
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study	4
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study	4
A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms	4
Why, whether and how to use high-flow nasal therapy in acute exacerbations of chronic obstructive pulmonary disease	4
Are eSports more than just sitting? A study comparing energy expenditure	4
Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA	4
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting	4
Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims	4
Resource utilization and economic outcomes following repetitive transcranial magnetic stimulation for treatment-resistant depression: a retrospective observational analysis	4
How pharma can amplify product value with implementation science	4
Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study	4
Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants	4
Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes	4
Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses	4
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis	4
Sex-based differences in the outcomes of patients with lung carcinoids	4